Finance

Lists
Q2 2027 earnings • released • EPS beat +20,18% • Revenue beat +16,41%
See results
GLAXO:NSE
GlaxoSmithKline Pharmaceuticals Ltd
2 530,00 ₹
+1,19%
(+29,80) 1D
6 նոյ, 15:30:01 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for GLAXO...
Open
2 502,00 ₹
High
2 544,80 ₹
Low
2 489,30 ₹
Mkt. cap
428,60 մլրդ
Avg. vol.
71,18 հզր
Volume
117,40 հզր
Dividend
2,25%
Quarterly dividend
14,25 ₹
Ex-dividend date
29 մյս, 2026 թ.
P/E ratio
37,38
52-wk high
3 120,70 ₹
52-wk low
2 088,10 ₹
EPS
67,68 ₹
Shares outstanding
169,41 մլն
No. of employees
3 հզր
Open
2 502,00 ₹
High
2 544,80 ₹
Low
2 489,30 ₹
Mkt. cap
428,60 մլրդ
Avg. vol.
71,18 հզր
Volume
117,40 հզր
Dividend
2,25%
Quarterly dividend
14,25 ₹
Ex-dividend date
29 մյս, 2026 թ.
P/E ratio
37,38
52-wk high
3 120,70 ₹
52-wk low
2 088,10 ₹
EPS
67,68 ₹
Shares outstanding
169,41 մլն
No. of employees
3 հզր
News stories
From web sources and news partners
Profile
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
About GlaxoSmithKline Pharmaceuticals Ltd
CEO-
Employees3,1 հզր
Founded13 նոյ, 1924 թ.
Headquarters-
SectorHealth Care
Industry-
Websiteindia-pharma.gsk.com
Last report
03 նոյ, 2026 թ.
Fiscal period
Q2 2027
19,83 ₹ / 16,50 ₹
+20,18%beat
Revenue / Est. (INR)
12,56 մլրդ / 10,79 մլրդ
+16,41%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
2026 թ. սեպ
Revenue
10,41 մլրդ
9,95 մլրդ
9,38 մլրդ
12,56 մլրդ
Cost of goods sold
3,64 մլրդ
3,69 մլրդ
3,28 մլրդ
4,44 մլրդ
Cost of revenue
3,64 մլրդ
3,69 մլրդ
3,28 մլրդ
4,44 մլրդ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,52 մլրդ
2,95 մլրդ
1,59 մլրդ
1,70 մլրդ
Operating expense
3,26 մլրդ
2,84 մլրդ
3,31 մլրդ
3,52 մլրդ
Total operating expenses
6,90 մլրդ
6,53 մլրդ
6,59 մլրդ
7,97 մլրդ
Operating income
3,51 մլրդ
3,43 մլրդ
2,80 մլրդ
4,60 մլրդ
Other non operating income
321,20 մլն
-1,09 մլրդ
437,60 մլն
-
EBT including unusual items
4,00 մլրդ
3,73 մլրդ
3,22 մլրդ
4,59 մլրդ
EBT excluding unusual items
3,82 մլրդ
2,94 մլրդ
3,22 մլրդ
4,59 մլրդ
Income tax expense
1,04 մլրդ
952,41 մլն
852,70 մլն
1,23 մլրդ
Effective tax rate
26,08%
25,53%
26,44%
26,88%
Other operating expenses
1,54 մլրդ
-236,82 մլն
1,56 մլրդ
1,67 մլրդ
Net income
2,96 մլրդ
2,78 մլրդ
2,37 մլրդ
3,36 մլրդ
Net profit margin
28,39%
27,92%
25,27%
26,73%
Earnings per share
-
-
14,00
19,83
Interest and investment income
-
657,30 մլն
-
-
Interest expense
-11,90 մլն
-6,12 մլն
-9,70 մլն
-4,90 մլն
Net interest expenses
-11,90 մլն
651,18 մլն
-9,70 մլն
-4,90 մլն
Depreciation and amortization charges
203,20 մլն
131,74 մլն
158,40 մլն
150,20 մլն
EBITDA
3,61 մլրդ
3,52 մլրդ
2,89 մլրդ
4,75 մլրդ
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google Apps